Effect of tailoring biliopancreatic limb length based on total small bowel length versus standard limb length in one anastomosis gastric bypass: 1-year outcomes of the TAILOR randomized clinical superiority trial.

IF 8.6 1区 医学 Q1 SURGERY British Journal of Surgery Pub Date : 2024-08-30 DOI:10.1093/bjs/znae219
Nienke Slagter, Lindsy van der Laan, Loek J M de Heide, Ewoud H Jutte, Mirjam A Kaijser, Stefan L Damen, André P van Beek, Marloes Emous
{"title":"Effect of tailoring biliopancreatic limb length based on total small bowel length versus standard limb length in one anastomosis gastric bypass: 1-year outcomes of the TAILOR randomized clinical superiority trial.","authors":"Nienke Slagter, Lindsy van der Laan, Loek J M de Heide, Ewoud H Jutte, Mirjam A Kaijser, Stefan L Damen, André P van Beek, Marloes Emous","doi":"10.1093/bjs/znae219","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tailoring the biliopancreatic limb length in one anastomosis gastric bypass is proposed as beneficial in retrospective studies, yet randomized trials are lacking. The aim of this double-blind, single-centre RCT was to ascertain whether tailoring biliopancreatic limb length based on total small bowel length (TSBL) results in superior outcomes after one anastomosis gastric bypass compared with a fixed 150 cm biliopancreatic limb length.</p><p><strong>Methods: </strong>Eligible patients, meeting International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) criteria for metabolic bariatric surgery, scheduled for primary one anastomosis gastric bypass surgery, and willing to be randomized, underwent TSBL measurement during surgery. When TSBL measurement was feasible, patients were randomly assigned to a standard 150 cm biliopancreatic limb length or a tailored biliopancreatic limb based on TSBL: TSBL less than 500 cm, biliopancreatic limb 150 cm; TSBL 500-700 cm, biliopancreatic limb 180 cm; and TSBL greater than 700 cm, biliopancreatic limb 210 cm. The primary outcome was percentage total weight loss at 5 years.</p><p><strong>Results: </strong>Between September 2020 and August 2022, 212 patients were randomized into the standard biliopancreatic limb group (105 patients) or the tailored biliopancreatic limb group (107 patients). The mean(s.d.) TSBL was 657(128) cm (range 295-1020 cm). In the tailored group, 150, 180, and 210 cm biliopancreatic limb lengths were applied to 8.4%, 53.3%, and 38.3% of patients respectively. The mean(s.d.) 1-year percentage total weight loss was 32.8(6.9)% in the standard group and 33.1(6.2)% in the tailored group (P = 0.787). Nutritional deficiencies and short-term complications showed no significant differences.</p><p><strong>Conclusion: </strong>Tailoring biliopancreatic limb length based on TSBL is safe and feasible. One year after surgery, it is not superior to a standard biliopancreatic limb length of 150 cm in terms of percentage total weight loss.</p><p><strong>Registration number: </strong>Dutch Trial Register, NL7945.</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":null,"pages":null},"PeriodicalIF":8.6000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363871/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjs/znae219","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tailoring the biliopancreatic limb length in one anastomosis gastric bypass is proposed as beneficial in retrospective studies, yet randomized trials are lacking. The aim of this double-blind, single-centre RCT was to ascertain whether tailoring biliopancreatic limb length based on total small bowel length (TSBL) results in superior outcomes after one anastomosis gastric bypass compared with a fixed 150 cm biliopancreatic limb length.

Methods: Eligible patients, meeting International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) criteria for metabolic bariatric surgery, scheduled for primary one anastomosis gastric bypass surgery, and willing to be randomized, underwent TSBL measurement during surgery. When TSBL measurement was feasible, patients were randomly assigned to a standard 150 cm biliopancreatic limb length or a tailored biliopancreatic limb based on TSBL: TSBL less than 500 cm, biliopancreatic limb 150 cm; TSBL 500-700 cm, biliopancreatic limb 180 cm; and TSBL greater than 700 cm, biliopancreatic limb 210 cm. The primary outcome was percentage total weight loss at 5 years.

Results: Between September 2020 and August 2022, 212 patients were randomized into the standard biliopancreatic limb group (105 patients) or the tailored biliopancreatic limb group (107 patients). The mean(s.d.) TSBL was 657(128) cm (range 295-1020 cm). In the tailored group, 150, 180, and 210 cm biliopancreatic limb lengths were applied to 8.4%, 53.3%, and 38.3% of patients respectively. The mean(s.d.) 1-year percentage total weight loss was 32.8(6.9)% in the standard group and 33.1(6.2)% in the tailored group (P = 0.787). Nutritional deficiencies and short-term complications showed no significant differences.

Conclusion: Tailoring biliopancreatic limb length based on TSBL is safe and feasible. One year after surgery, it is not superior to a standard biliopancreatic limb length of 150 cm in terms of percentage total weight loss.

Registration number: Dutch Trial Register, NL7945.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在单吻合胃旁路术中,根据小肠总长度定制胆胰管肢体长度与标准肢体长度的对比效果:TAILOR 随机临床优越性试验的 1 年结果。
背景:回顾性研究认为,在一次吻合胃旁路术中定制胆胰管肢体长度是有益的,但目前还缺乏随机试验。这项双盲、单中心 RCT 的目的是确定根据小肠总长度(TSBL)定制胆胰管肢体长度与固定的 150 厘米胆胰管肢体长度相比,是否能在一次吻合胃旁路术后获得更好的疗效:方法:符合国际肥胖和代谢紊乱外科联合会(IFSO)代谢减肥手术标准、计划接受一次吻合胃旁路手术并愿意接受随机分组的合格患者在手术期间接受 TSBL 测量。如果可以进行TSBL测量,患者将被随机分配到标准的150厘米胆胰管肢体长度或根据TSBL定制的胆胰管肢体:TSBL小于500厘米,胆胰管肢体长度为150厘米;TSBL为500-700厘米,胆胰管肢体长度为180厘米;TSBL大于700厘米,胆胰管肢体长度为210厘米。主要结果是5年后总重量下降的百分比:2020年9月至2022年8月,212名患者被随机分为标准胆胰管肢体组(105名)或定制胆胰管肢体组(107名)。TSBL的平均值(s.d.)为657(128)厘米(范围为295-1020厘米)。在定制组中,分别有8.4%、53.3%和38.3%的患者采用了150、180和210厘米的胆胰管肢体长度。标准组 1 年总重量下降的平均百分比(s.d.)为 32.8(6.9)%,定制组为 33.1(6.2)%(P = 0.787)。营养缺乏和短期并发症无明显差异:结论:根据TSBL定制胆胰管肢体长度是安全可行的。结论:根据 TSBL 定制胆胰管肢体长度是安全可行的,术后一年,就总重量减少的百分比而言,它并不比 150 厘米的标准胆胰管肢体长度更有优势:注册编号:荷兰试验注册,NL7945。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
12.70
自引率
7.30%
发文量
1102
审稿时长
1.5 months
期刊介绍: The British Journal of Surgery (BJS), incorporating the European Journal of Surgery, stands as Europe's leading peer-reviewed surgical journal. It serves as an invaluable platform for presenting high-quality clinical and laboratory-based research across a wide range of surgical topics. In addition to providing a comprehensive coverage of traditional surgical practices, BJS also showcases emerging areas in the field, such as minimally invasive therapy and interventional radiology. While the journal appeals to general surgeons, it also holds relevance for specialty surgeons and professionals working in closely related fields. By presenting cutting-edge research and advancements, BJS aims to revolutionize the way surgical knowledge is shared and contribute to the ongoing progress of the surgical community.
期刊最新文献
Curative-intent ablation margins (A0) for colorectal liver metastasis: more burning questions. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Effect of tailoring biliopancreatic limb length based on total small bowel length versus standard limb length in one anastomosis gastric bypass: 1-year outcomes of the TAILOR randomized clinical superiority trial. Identification of A0 minimum ablative margins for colorectal liver metastases: multicentre, retrospective study using deformable CT registration and artificial intelligence-based autosegmentation. Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1